BioVaxys Technology Corp.

    BioVaxys Technology Corp.

    CCSE:BIOV
    0.07
    CAD
    0.00
    (0.00%)
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Basic EPS, GAAP
    - -
    -0.22
    -0.42
    -0.78
    -1.19
    -0.57
    -0.2
    -0.25
    Free Cash Flow per Basic Share
    - -
    -0.22
    -0.43
    -0.64
    -0.16
    -0.08
    -0.2
    -0.09
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -0.04
    0.09
    1.29
    0.89
    -0.07
    -0.23
    -0.07
    -0.09
    Tangible Book Value per Share
    -0.04
    0.09
    0.29
    0.08
    -0.07
    -0.23
    -0.07
    -0.09
    Basic Weighted Avg Shares
    - -
    1
    3
    8
    10
    13
    20
    26
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Net Income, GAAP
    - -
    - -
    -1
    -6
    -12
    -8
    -4
    -6
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Working Capital
    - -
    - -
    2
    1
    -1
    -3
    -2
    -3
    LT Debt
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Total Equity
    - -
    - -
    10
    8
    -1
    -3
    -2
    -3
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    -24.09
    -72.82
    - -
    - -
    - -
    - -

    Capital Structure

    CAD

    •

    in mil. unless spec.
    Oct'24
    Jan'25
    Apr'25
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    26
    29
    29
    Market Capitalization
    2
    2
    1

    Working Capital

    CAD

    •

    in mil. unless spec.
    Oct'24
    Jan'25
    Apr'25
    Total Current Assets
    1
    1
    1
    Cash, Cash Equivalents & STI
    - -
    - -
    - -
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    3
    3
    4
    Payables & Accruals
    3
    3
    4
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    CAD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    1,019.39%
    -43.06%
    Free Cash Flow
    - -
    187.35%
    276.83%
    Net Income, GAAP
    - -
    171.77%
    -48.55%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.08
    -0.11
    -0.02
    - -
    -0.57
    2024
    0.04
    -0.03
    -0.05
    - -
    -0.2
    2025
    -0.04
    -0.05
    - -
    - -
    - -

    Quarterly Dividends Per Share

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • newsfilecorp.com

      BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

    • thenewswire.com

      BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

    • thenewswire.com

      BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

    • thenewswire.com

      BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

    • thenewswire.com

      BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

    • thenewswire.com

      BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

    • thenewswire.com

      BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

    • thenewswire.com

      BioVaxys Announces Application for Management Cease Trade Order

    • thenewswire.com

      BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

    • newsfilecorp.com

      BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

    • thenewswire.com

      BioVaxys 1Q2026 R&D and Collaborative Activity

    • newsfilecorp.com

      BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

    • thenewswire.com

      2025 Corporate Review

    • newsfilecorp.com

      BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

    • thenewswire.com

      BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D

    • thenewswire.com

      BioVaxys Technology Corp. Closes Debt Settlement Transaction

    • businesswire.com

      BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement

    • thenewswire.com

      BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement

    • prnewswire.com

      BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

    • newsfilecorp.com

      CSE Bulletin: Consolidation - BioVaxys Technology Corp. (BIOV)